share_log

Truist Securities Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $160

Truist Securities Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $160

Truist 证券维持对CRISPR Therapeutics的买入,将目标股价下调至160美元
Benzinga ·  2023/12/11 11:31

Truist Securities analyst Joon Lee maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $220 to $160.

Truist Securities分析师李俊维持CRISPR Therapeutics(纳斯达克股票代码:CRSP)的买入,并将目标股价从220美元下调至160美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发